362例早期鼻咽癌单纯放疗疗效分析

目的 分析早期鼻咽癌患者单纯放疗的长期疗效及不同T与N分期对预后影响.方法 搜集接受单纯放疗的362例早期(T1～T2 N0～1M0期,1992年福州分期)鼻咽癌初治患者的临床资料做回顾分析.结果 中位随访70个月,全组病例5年总生存率为85.0%.T1N0、T2N0和T1N1期5年总生存率分别为96.6%、91.3%和85.8%(χ2=3.83,P＞0.05),T2N1期的(73.1%)比前3个期别明显减低(χ2=30.0,P＜0.05),而4个期别的5年无局部复发生存率和无区域复发生存率均无差异.T1N0、T2N0和T1N1期5年无远处转移生存率分别为94.9%、97.5%和95.6%(χ2=0.53,P＞0.05),T2N1期的(81.2%)比前3个期的明显减低(χ2=26.6,P＜0.05).结论 单纯常规放疗对T1N0、T2N0和T1N1期患者可获得满意疗效.T2N1M0期的疗效明显差于前3个期别,其治疗失败的主要原因是远处转移.针对T2N1M0期筛选容易发生远处转移的个体给予放化综合治疗是下一步研究方向.

Treatment result of radiotherapy alone for patients with early stage nasopharyngeal carcinoma

Objective To analyze the treatment result of radiotherapy alone for patients with early stage nasopharyngeal carcinoma (NPC) and discuss the impact of T and N stages on the prognois. Methods From January 1999 to December 2001, clinical data of 362 patients with early stage (T1-2N0-1M0,92'Fuzhou staging system) NPC treated by radiotherapy alone were reviewed. Results Median follow-up time was 70 months. The 5-year overall survival (OS) rate of the whole group was 85%. The 5-year OS rates of patients with T1N0,T2N0 and T1N1 disease were 96.6% ,91.3% and 85.8% ,which were not statistically different ( χ2 = 3.83, P ＞ 0.05). The 5-year OS rate of those with T2N1 disease was 73.1%,which was sta tistically different from the former three groups ( χ2 = 30.0 ,P ＜ 0.05 ). The 5-year local-recurrence free sur vival and 5-year regional-recurrence free survival rates had no significant difference among the four groups.The 5-year distant-metastasis free survival rates of the former three, groups were 94.9% ,97.5% and 95.6% (χ2 = 0.53, P ＞0.05). The rate of patients with T2N1 disease was 81.2%, which was significantly different from the others (χ2 =26.6,P 0.05).Conclusions Radiotherapy alone for T1N0,T2N0 and T1N1 naso pharyngeal carcinoma has a satisfactory result. With more failure of distant metastasis, patients with T2N1 disease has obviously poorer outcome than the others. Patients who have high risk of distant metastasis may need combined treatment instead of radiotherapy alone in the future study.